Multiple sclerosis (MS) is an inflammatory, immunemediated disease of the CNS that classically was thought to involve primarily the white matter. More recently, gray matter involvement has been recognized, in part through the use of new MRI techniques. However, MRI is far from perfect for detecting neocortical tissue damage in MS, particularly confluent subpial demyelination that can be quite extensive. 1 Subpial lesions seem to be especially prominent in cases of progressive MS, in which disability accumulates relentlessly over time, and they are thus thought to play a pathogenic role.
The origin of subpial cortical lesions is unknown, in part because their poor visualization by MRI limits our ability to study their development and natural history. However, accumulating pathologic datafrom biopsies early in the disease 2 and autopsies at its end 3 -suggest that these lesions might occur in association with inflammatory infiltrates in the leptomeninges. Indeed, leptomeningeal inflammation was recognized in up to 41% of MS cases several decades ago, 4 and in some cases such inflammation may organize into follicle-like structures that may help sustain an abnormal immune response within the CNS. 5 However, despite a prior case report of diffuse pachymeningeal contrast enhancement in MS, 6 leptomeningeal enhancement is traditionally considered a finding that should suggest a diagnosis other than MS. 7 T2-weighted fluid-attenuated inversion recovery (T2 FLAIR) MRI scanning performed after IV injection of a gadolinium-based contrast agent has shown promise in detecting inflammation in the leptomeningeal compartment 8 ; in this context, it is superior to conventional T1-weighted imaging. 9 It is important to note that postcontrast T2 FLAIR MRI does not detect leptomeningeal inflammation directly; rather, it is sensitive to the associated vascular leakage. In this sense, it is similar to gadolinium enhancement in new white matter lesions in MS, which is closely associated with, but does not directly demonstrate, inflammation. 10 Indeed, pathologic descriptions of leptomeningeal inflammatory infiltrates suggest that they are typically too small to be directly visible even on high-resolution MRI scans, which typically have a spatial resolution on the order of 1 mm 3 . Recently, one of us has reported that postcontrast T2 FLAIR demonstrates focal, usually perivascular, and sometimes subtle leptomeningeal contrast enhancement in approximately 25% of MS cases overall-but nearly 40% of cases of MS with progressive onset. 11 In these studies, enhancement was generally stable over a period of several years, consistent with the notion that it could indicate persistent inflammatory infiltration of the meninges (as described in autopsy studies). Furthermore, pathologic evaluation in 2 cases that came to autopsy demonstrated the presence of perivascular leptomeningeal inflammation within sulci that enhanced in vivo. 12 Against this background, in this issue of Neurology ® , Eisele and coworkers 13 report their own experience in applying postcontrast T2 FLAIR at 3T to 112 persons with MS, observing focal leptomeningeal enhancement in only a single MS case-in association with a gadolinium-enhancing lesion that was somewhat unusual in its involvement of the neocortex. These researchers also studied 5 individuals with stroke as a positive disease control group, all of whom showed more diffuse leptomeningeal enhancement in a pattern consistent with prior descriptions in stroke 14 but very different from the focal enhancement described by Reich et al. 11 in MS. Eisele et al. 13 show convincingly that leptomeningeal enhancement of the type seen in stroke is not prevalent in MS. Strong points of the work include the acquisition of both precontrast and postcontrast T2 FLAIR and blinding of the readers. Potential weaknesses include use of a standard dose of gadolinium and a relative short wash-in time, but also the relative paucity of subjects with progressive disease.
There are similarities between the studies of Reich et al. and Eisele et al. (neither group found diffuse leptomeningeal enhancement to be a characteristic of MS), but there are important differences as well (including the patient populations and particular implementation of the postcontrast T2 FLAIR imaging technique). Future work by others should determine the actual prevalence of leptomeningeal contrast enhancement in MS, as well as its natural history, clinical relevance, and, importantly, treatment responsiveness. Moving to 7T may be advantageous or alternatively using higher doses of contrast and longer postinjection delays. Ultimately, the noninvasive in vivo detection of leptomeningeal inflammation, and the elucidation of its association with tissue damage in the brain (in particular subpial cortical demyelination), represent exciting new developments in the application of MRI to MS.
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